UBS likes Pfizer’s MTSR obesity deal but stays neutral on PFE

Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of ...

Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer (PFE) navigates patent losses with strategic cost controls, BMO Capital reaffirms outperform rating

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc.

Pfizer 2026: The Reset Year

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read my latest analysis of PFE stock.